U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
[Business Wire] – AstraZeneca today announced that the U.S. Food and Drug Administration has approved the Bydureon® Pen 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. moreView todays social media effects on AZNView the latest stocks trending across Twitter. Click to view dashboardSee who Astrazeneca is hiring next, click […]